Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing
Top Cited Papers
- 29 August 2013
- journal article
- practice guideline
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 94 (6), 640-645
- https://doi.org/10.1038/clpt.2013.172
Abstract
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD, encoded by the DPYD gene), and reduced or absent activity of this enzyme can result in severe, and sometimes fatal, toxicity. We summarize evidence from the published literature supporting this association and provide dosing recommendations for fluoropyrimidines based on DPYD genotype (updates at http://www.pharmgkb.org).Keywords
This publication has 39 references indexed in Scilit:
- Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian populationComptes Rendus Biologies, 2007
- 5-Fluorouracil-related severe toxicity: A comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiencyCancer Letters, 2007
- Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil toleranceMolecular Cancer Therapeutics, 2006
- Comprehensive analysis of pyrimidine metabolism in 450 children with unspecific neurological symptoms using high–pressure liquid chromatography–electrospray ionization tandem mass spectrometryJournal of Inherited Metabolic Disease, 2005
- Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicityBritish Journal of Cancer, 1999
- Characterization of the Human Dihydropyrimidine Dehydrogenase GeneGenomics, 1998
- Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235WHuman Genetics, 1997
- Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicityEuropean Journal of Cancer, 1997
- Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity.JCI Insight, 1996
- Population study of dihydropyrimidine dehydrogenase in cancer patients.Journal of Clinical Oncology, 1994